Drug Trial Radar · NCT04510298
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Oct 15, 2020
Primary completion
Apr 15, 2021
Study completion Apr 15, 2021
Sponsor
- Lead sponsor
- Sirtsei Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
Conditions
- Schizophrenia
Interventions
SP-624Drug
Oral Capsule
PlaceboDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Up to 8 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Research
Garden Grove, California
Hassman Research Institute
Marlton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.